Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$50.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 69.8% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$171.0 million, a 154.69% decrease from a year earlier, with the FY2025 full-year figure at -$161.2 million, down 119.71% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$50.0 million, up from -$84.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for FULC reached as high as $55.4 million in Q2 2024 and fell as low as -$192.5 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$45.5 million across 5 years, with a median of -$30.5 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders sank 310.77% in 2022 and jumped 332.98% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$192.5 million in 2022, then surged by 77.6% to -$43.1 million in 2023, then tumbled by 65.71% to -$71.4 million in 2024, then declined by 17.81% to -$84.2 million in 2025, then jumped by 40.62% to -$50.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$50.0 million in Q1 2026, -$84.2 million in Q4 2025, and -$19.6 million in Q3 2025.